Showing 8481-8490 of 9370 results for "".
- Dyskerin May Signal When SCC Is On The Movehttps://practicaldermatology.com/news/dyskerin-may-signal-when-scc-is-on-the-move/2461585/The protein dyskerin may provide important clues as to how cutaneous squamous cell carcinoma tumors prepare themselves to migrate to the lymph nodes to metastasize other organs, a new study suggests. These cells stop consuming glucose so that they can survive by using LDL chol
- Incyte Receives Positive CHMP Opinion for Opzelura Cream for the Treatment of Non-Segmental Vitiligohttps://practicaldermatology.com/news/incyte-receives-positive-chmp-opinion-for-opzelura-cream-for-the-treatment-of-non-segmental-vitiligo/2461576/The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of ruxolitinib cream (Opzelura) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
- FDA Gives Nod to First Particulate Placental Extracellular Matrix Medical Device for Wound Managementhttps://practicaldermatology.com/news/fda-gives-nod-to-first-particulate-placental-extracellular-matrix-medical-device-for-wound-management/2461574/The U.S. Food and Drug Administration cleared Convatec’s InnovaMatrix PD particulate placental extracellular matrix medical device for wound management. The InnovaMatrix PD medical device joins Convatec’s existing InnovaMatrix AC product as the first and only next-gener
- Exosome Update: Evolve Skincare to Distribute Elevai Skin Care Products in Canadahttps://practicaldermatology.com/news/exosome-update-evolve-skincare-to-distribute-elevai-skin-care-products-in-canada/2461572/Evolve Medical Inc. is the exclusive distributor for Elevai Skincare products in Canada. The Elevai E-Series product range, a pre-and post-procedure skincare system developed with a proprietary stem cell exosome technology, will now be available to dermatologists
- Relief Therapeutics Enrolls First Patients in Proof-of-Concept Trial of Epidermolysis Bullosa Treatmenthttps://practicaldermatology.com/news/relief-therapeutics-enrolls-first-patients-in-proof-of-concept-trial-of-epidermolysis-bullosa-treatment/2461563/Relief Therapeutics announced the first three patients have been enrolled in a proof-of-concept, investigator-initiated study to evaluate RLF-TD011 as a treatment for epidermolysis bullosa (EB). The primary aim of the study will be to assess changes in the skin microbiome (Staphylococcu
- Potential Notalgia Paresthetica Breakthrough: Oral Difelikefalin May Curb Persistent Itchhttps://practicaldermatology.com/news/potential-notalgia-paresthetica-breakthrough-oral-difelikefalin-may-curb-persistent-itch/2461553/Notalgia paresthetica—a nerve disorder characterized by a persistent itch in the upper back—is a common and underdiagnosed condition worldwide. To date, there are no U.S. Food and Drug Administration (FDA)-approved treatments specifically targeting this disorder. But a new s
- Medical Groups Offer Updated Guidance on Hand Hygiene in Healthcare Settingshttps://practicaldermatology.com/news/groups-offer-updated-guidance-on-hand-hygiene-in-healthcare-settings/2461551/Five medical organizations are recommending updated best practices for hand hygiene to protect patients and staff in healthcare settings. The new recommendations emphasize the importance of healthy skin and nails and easy access to alcohol-based hand sanitizers. Strategi
- Study: Six Percent of Children Have Eczema Symptoms Worldwidehttps://practicaldermatology.com/news/study-six-percent-of-children-have-eczema-symptoms-worldwide/2461550/About 6% of children and adolescents have some form of eczema, according to New research published in Clinical & Experimental Allergy. In addition, 0.6% of children and 1.1% of adolescents across the g
- MTX Use May Up Risk for Three Types of Skin Cancerhttps://practicaldermatology.com/news/mtx-use-may-up-skin-cancer-risk/2461546/Methotrexate (MTX) may increase risk for three types of skin cancer, according to a new study out of University of Gothenburg. Patients receiving the drug include those with moderate to severe psoriasis; but in this particular patient group, a risk increase was only observed for basal c
- Escient Pharmaceuticals Receives FDA IND Clearance to Start Phase 1 Study of EP262https://practicaldermatology.com/news/escient-pharmaceuticals-receives-fda-ind-clearance-to-start-phase-1-study-of-ep262/2461542/The FDA has cleared Escient Pharmaceuticals’ investigational new drug (IND) application for EP262. The clearance allows the Escient to initiate a Phase 1 first-in-human study for the company’s second drug candidate to be advanced into clinical development. EP262 is a first-i